Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Mar 2022
Price :
$35
*
At a glance
- Drugs Brodalumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 03 Feb 2022 Status changed from completed to discontinued.
- 03 Feb 2022 Status changed from completed to discontinued.
- 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.